The management of relapsed and refractory multiple myeloma (RRMM) continues to be challenging though new therapeutics for the disease have been emerging in recent decades. Essentially, while decreased survival was observed in each extra line of therapy, clinical opinion commented that 38% of patients with RRMM receives third-line treatment. Thus, appropriate selection of regimen for each line of treatment aiming to improve survival for patients with RRMM is crucial. On 7th December, 2021, a hybrid lecture organised by the Hong Kong Society of Myeloma titled “Management of Relapsed or Refractory Multiple Myeloma” has been successfully organised.
Discussion among Prof. Sonneveld (left) and local clinicians was moderated by Prof. James Chim (right)
In the lecture, Prof. Pieter Sonneveld, Professor of Haematology at the Erasmus University of Rotterdam, presented the pathophysiology of RRMM and outlined the clinical treatment for the disease. He also highlighted the results of recent clinical trials evaluating the efficacy of newly developed therapeutics against myeloma. In particular, the outcomes of various combinations of immunomodulatory drugs (IMiDs)-based triplet regimens on relapse/refractory disease were discussed. The lecture was followed by fruitful discussion among the keynote speaker and audiences.
Prof. Sonneveld discussed the efficacy of IMiDs-based triplet therapy in RRMM
Prof. Sonneveld outlined the pathophysiology of RRMM
